Jeff Jones

“Question on the IRF5 program with KT579. As you look at those results coming late this year, is there anything that will guide you towards or away from particular indications beyond lupus?”

“Could you perhaps provide some color around the commercial launch efforts for Jowenja and the EU and how you're anticipating these to build and maybe speak a little bit more to the magnitude of the opportunity as you expand country to country.”

“Can you speak maybe mechanistically a little bit more to the difference in effect you're seeing in the HPV-positive patients? You mentioned Nectin-4 expression levels, and maybe then how you think about that impacting patient selection for the Phase III biomarkers and or subgroup analyses.”

“As we look ahead, 2026 and 27, where are you focusing in terms of growth? Is it more new accounts or is it driving greater use within existing accounts? And which do you see contributing to the greatest extent in your forward revenue growth?”

“Maybe following up on QTC activation with six on board and a target of seven by end of year, it seems a pretty low bar for you to get one more in by year. And just how are you thinking about building out additional QTCs as we look ahead into additional quarters and into next year?”